Drug
Mifepristone Daily
Mifepristone Daily: highest development phase Phase 2, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mifepristone 1200 mg daily NCT06689254 | Phase 2 | Treatment-resistant PTSD |
Latest
No recent events.
Follow Mifepristone Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.